Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27470302 | 0.81 | ERN1 (0.35) | ERN1AR | |
| SCHEMBL3285717 | 0.77 | — | — | |
| SCHEMBL27898096 | 0.76 | ERN1 (0.33) | ERN1 | |
| SCHEMBL1695206 | 0.74 | ALDH1A1 (0.32) | ERN1ALDH1A1HPGD | |
| SCHEMBL21354550 | 0.74 | TRPA1 (0.33) | NOTUMERN1HPGDTMPRSS4 | |
| SCHEMBL28013945 | 0.72 | ERN1 (0.34) | ERN1 | |
| SCHEMBL28982574 | 0.71 | ERN1 (0.36) | ERN1 | |
| SCHEMBL27547231 | 0.67 | NPBWR1 (0.37) | NOTUMERN1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL28292351 | 0.66 | ERN1 (0.35) | ERN1 | |
| SCHEMBL22084379 | 0.62 | ERN1 (0.41) | ERN1ALDH1A1HPGDHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 817 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068405-B1 | PYRROLO [1,2,F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2019-05-01 | — | — | EP | claimed |
| US-9714560-B2 | Protected scale inhibitors and methods relating thereto | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-07-25 | — | — | US | claimed |
| US-9493469-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| US-11999757-B2 | Synthesis of boronate ester derivatives and uses thereof | MELINTA SUBSIDIARY CORP. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240148885-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-09 | — | — | US | disclosed |
| EP-4356736-A2 | SYNTHESIS OF BORONATE SALTS | Melinta Therapeutics, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-3604316-B1 | SYNTHESIS OF BORONATE SALTS | MELINTA THERAPEUTICS INC (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023129737-A1 | GLYCOMIMETIC LIGANDS | AVICEDA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| EP-4149949-A1 | BORONIC ACID DERIVATIVES AND SYNTHESIS, POLYMORPHIC FORMS, AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-4122932-A1 | PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-1997049723-A1 | CATIONIC LIPIDS FOR DELIVERY OF NUCLEIC ACID TO CELLS | GILEAD SCIENCES, INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| US-5693771-A | REACTING PROTECTED PYRAN COMPOUND WITH PHOSPHITE AND HETEROCYCLIC BASE | GILEAD SCIENCES, INC. (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0807118-A2 | NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME | GILEAD SCIENCES, INC. (US) | 1997-11-19 | — | — | EP | disclosed |
| US-5659023-A | HETEROCYCLIC FURANOSYL OR PYRANOSYL PHOSPHONATE; IMMUNOGENS, OLIGONUCLEOTIDES, ANTIINFECTIVES, ANTIINFLAMMATORY AGENTS | GILEAD SCIENCES, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0759917-A1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES, INC. (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1996026933-A9 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | — | 1996-11-28 | — | — | WO | disclosed |
| WO-1996033200-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | ÚSTAV ORGANICKÉ CHEMIE A BIOCHEMIE AKADEMIE VED C^¿ESKÉ REPUBLIKY (CZ) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996023801-A2 | NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME | GILEAD SCIENCES, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | NOTUM 1438/4885ERN1 3489/4885ALDH1A1 1562/4885 |
| US-11999757-B2 | Synthesis of boronate ester derivatives and uses thereof | ADH5, ADH1A, ADH7 | NOTUM 138/4885ERN1 1035/4885ALDH1A1 69/4885 |
| US-20240148885-A1 | TARGETED BIFUNCTIONAL DEGRADERS | PSEN2, MDM2, UCHL1 | NOTUM 4051/4885ERN1 1756/4885ALDH1A1 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.